Filtered By:
Source: Circulation

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 925 results found since Jan 2013.

Social Vulnerability and Premature Cardiovascular Mortality Among US Counties, 2014 to 2018
CONCLUSIONS: In this analysis, US counties with more social vulnerabilities had higher premature CVD mortality, varied by demographic characteristics and rurality. Focused public health interventions should address the socioeconomic disparities faced by underserved communities to curb the growing burden of premature CVD.PMID:34662161 | DOI:10.1161/CIRCULATIONAHA.121.054516
Source: Circulation - October 18, 2021 Category: Cardiology Authors: Safi U Khan Zulqarnain Javed Ahmad N Lone Sourbha S Dani Zahir Amin Sadeer G Al-Kindi Salim S Virani Garima Sharma Ron Blankstein Michael J Blaha Miguel Cainzos-Achirica Khurram Nasir Source Type: research

Predictors of Development of Atrial Fibrillation in Patients With Embolic Stroke Of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
Conclusions: Besides age as the most important variable, several other factors, including hypertension, higher body mass index, and lack of diabetes, are independent predictors of AF after ESUS. When baseline NT-proBNP was available, only older age and elevation of this biomarker were predictive of subsequent AF. Understanding who is at higher risk of developing AF will assist in identifying patients who may benefit from more intense, long-term cardiac monitoring.PMID:34649459 | DOI:10.1161/CIRCULATIONAHA.121.055176
Source: Circulation - October 15, 2021 Category: Cardiology Authors: Maria Cecilia Bahit Ralph L Sacco J Donald Easton Juliane Meyerhoff Lisa Cronin Eva Kleine Claudia Grauer Martina Brueckmann Hans-Christoph Diener Renato D Lopes Michael Brainin Philippe Lyrer Rolf Wachter Tomas Segura Christopher B Granger Source Type: research

Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD
Conclusions: After LER for symptomatic PAD, ALI is frequent, particularly early after LER, and is associated with poor prognosis. Low-dose rivaroxaban plus aspirin reduces ALI after LER, including ALI events associated with the most severe outcomes. The benefit of rivaroxaban for ALI appears early, continues over time, and is consistent regardless of revascularization approach or clopidogrel use.PMID:34637332 | DOI:10.1161/CIRCULATIONAHA.121.055146
Source: Circulation - October 12, 2021 Category: Cardiology Authors: Connie N Hess E Sebastian Debus Mark R Nehler Sonia S Anand Manesh R Patel Michael Szarek Warren H Capell Judith Hsia Joshua A Beckman Marianne Brodmann Rafael Diaz Peter Habertheuer Nicholas J Leeper Richard J Powell Henrik Sillesen Eva Muehlhofer Scott Source Type: research

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
Conclusions: Rates of NACE and MACCE did not differ with abbreviated APT in high bleeding risk patients with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier:NCT03023020.PMID:34455849 | DOI:10.1161/CIRCULATIONAHA.121.056680
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Pieter C Smits Enrico Frigoli Jan Tijssen Peter J üni Pascal Vranckx Yukio Ozaki Marie-Claude Morice Bernard Chevalier Yoshinobu Onuma Stephan Windecker Pim A L Tonino Marco Roffi Maciej Lesiak Felix Mahfoud Jozef Bartunek David Hildick-Smith Antonio Col Source Type: research

Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Conclusions: PRONOUNCE is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely due to smaller than planned number of participants and events and no difference in MACE at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02663908.PMID:34459214 | DOI:10.1161/CIRCULATIONAHA.121.056810
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Renato D Lopes Celestia S Higano Susan F Slovin Adam J Nelson Robert Bigelow Per S S ørensen Chiara Melloni Shaun G Goodman Christopher P Evans Jan Nilsson Deepak L Bhatt Noel W Clarke Tine K Olesen Belinda T Doyle-Olsen Henriette Kristensen Lauren Arney Source Type: research

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
Conclusions: Rates of NACE and MACCE did not differ with abbreviated APT in high bleeding risk patients with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier:NCT03023020.PMID:34455849 | DOI:10.1161/CIRCULATIONAHA.121.056680
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Pieter C Smits Enrico Frigoli Jan Tijssen Peter J üni Pascal Vranckx Yukio Ozaki Marie-Claude Morice Bernard Chevalier Yoshinobu Onuma Stephan Windecker Pim A L Tonino Marco Roffi Maciej Lesiak Felix Mahfoud Jozef Bartunek David Hildick-Smith Antonio Col Source Type: research

Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Conclusions: PRONOUNCE is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely due to smaller than planned number of participants and events and no difference in MACE at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02663908.PMID:34459214 | DOI:10.1161/CIRCULATIONAHA.121.056810
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Renato D Lopes Celestia S Higano Susan F Slovin Adam J Nelson Robert Bigelow Per S S ørensen Chiara Melloni Shaun G Goodman Christopher P Evans Jan Nilsson Deepak L Bhatt Noel W Clarke Tine K Olesen Belinda T Doyle-Olsen Henriette Kristensen Lauren Arney Source Type: research